Impact of Cardiac Implantable Electronic Device Infection: A Clinical and Economic Analysis of the WRAP-IT Trial
| Autor: | Bruce L. Wilkoff, Suneet Mittal, Daniel R. Lexcen, Giuseppe Boriani, Reece Holbrook, G. Ralph Corey, Svein Faerestrand, John C. Love, Charles Kennergren, Ralph Augostini, Sherman S Wiggins, Jeanne E. Poole, Khaldoun G. Tarakji, Jeffrey D. Lande, Sarah Willey, Jeff S. Healey |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
Pacemaker Artificial Time Factors Treatment outcome Cause of Death antibiotic Economic analysis Single-Blind Method Prospective Studies infections Hospital Costs Prosthesis-Related Infection Antibiotic prophylaxis Aged 80 and over Medical record Fee-for-Service Plans Health Care Costs Middle Aged Anti-Bacterial Agents Defibrillators Implantable Treatment Outcome administrative claims economics healthcare quality of life ComputingMethodologies_DOCUMENTANDTEXTPROCESSING Health Resources Female Cardiology and Cardiovascular Medicine administrative claims healthcare medicine.medical_specialty Prosthesis-Related Infections Medicare Patient Readmission Drug Costs Device removal Physiology (medical) medicine Humans Intensive care medicine Device Removal Aged business.industry Original Articles Antibiotic Prophylaxis Length of Stay United States Administrative claims Health Expenditures business |
| Zdroj: | Circulation. Arrhythmia and Electrophysiology |
| Popis: | Supplemental Digital Content is available in the text. Background: Current understanding of the impact of cardiac implantable electronic device (CIED) infection is based on retrospective analyses from medical records or administrative claims data. The WRAP-IT (Worldwide Randomized Antibiotic Envelope Infection Prevention Trial) offers an opportunity to evaluate the clinical and economic impacts of CIED infection from the hospital, payer, and patient perspectives in the US healthcare system. Methods: This was a prespecified, as-treated analysis evaluating outcomes related to major CIED infections: mortality, quality of life, disruption of CIED therapy, healthcare utilization, and costs. Payer costs were assigned using medicare fee for service national payments, while medicare advantage, hospital, and patient costs were derived from similar hospital admissions in administrative datasets. Results: Major CIED infection was associated with increased all-cause mortality (12-month risk-adjusted hazard ratio, 3.41 [95% CI, 1.81–6.41]; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|